A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose We examined the efficacy of poziotinib, a second-generation epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) in patients with lung adenocarcinoma with activating EGFR mutations, who developed acquired resistance (AR) to EGFR-TKIs. Materials and Methods This single-arm phase II study included EGFR-mutant lung adenocarcinoma with AR to erlotinib or gefitinib based on the Jackman criteria. Patients received poziotinib 16 mg orally once daily in a 28-day cycle. The primary endpoint was progression-free survival (PFS). Prestudy tumor biopsies and blood samples were obtained to determine resistance mechanisms. Results Thirty-nine patients were treated. Tumor genotyping was determined in 37 patients; 19 EGFR T790M mutations and two PIK3CAmutations were detected in the prestudy tumors, and seven T790M mutations were detected in the plasma assay. Three (8%; 95% confidence interval [CI], 2 to 21) and 17 (44%; 95% CI, 28 to 60) patients had partial response and stable disease, respectively. The median PFS and overall survival were 2.7 months (95% CI, 1.8 to 3.7) and 15.0 months (95% CI, 9.5 to not estimable), respectively. A longer PFS was observed for patients without T790M or PIK3CA mutations in tumor or plasma compared to those with these mutations (5.5 months vs. 1.8 months, p=0.003). The most frequent grade 3 adverse events were rash (59%), mucosal inflammation (26%), and stomatitis (18%). Most patients required one (n=15) or two (n=15) dose reductions. Conclusion Low activity of poziotinib was detected in patients with EGFR-mutant non-small cell lung cancer who developed AR to gefitinib or erlotinib, potentially because of severe-toxicityimposed dose limitation.
Abstract
Purpose We examined the efficacy of poziotinib, a second-generation epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) in patients with lung adenocarcinoma with activating EGFR mutations, who developed acquired resistance (AR) to EGFR-TKIs. Materials and Methods This single-arm phase II study included EGFR-mutant lung adenocarcinoma with AR to erlotinib or gefitinib based on the Jackman criteria. Patients received poziotinib 16 mg orally once daily in a 28-day cycle. The primary endpoint was progression-free survival (PFS). Prestudy tumor biopsies and blood samples were obtained to determine resistance mechanisms. Results Thirty-nine patients were treated. Tumor genotyping was determined in 37 patients; 19 EGFR T790M mutations and two PIK3CAmutations were detected in the prestudy tumors, and seven T790M mutations were detected in the plasma assay. Three (8%; 95% confidence interval [CI], 2 to 21) and 17 (44%; 95% CI, 28 to 60) patients had partial response and stable disease, respectively. The median PFS and overall survival were 2.7 months (95% CI, 1.8 to 3.7) and 15.0 months (95% CI, 9.5 to not estimable), respectively. A longer PFS was observed for patients without T790M or PIK3CA mutations in tumor or plasma compared to those with these mutations (5.5 months vs. 1.8 months, p=0.003). The most frequent grade 3 adverse events were rash (59%), mucosal inflammation (26%), and stomatitis (18%). Most patients required one (n=15) or two (n=15) dose reductions. Conclusion Low activity of poziotinib was detected in patients with EGFR-mutant non-small cell lung cancer who developed AR to gefitinib or erlotinib, potentially because of severe-toxicityimposed dose limitation.
참고문헌 (21)
- Maemondo M, "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR", N Engl J Med, 362, pp.2380~2388 (2010)
- Zhou C, "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer(OPTIMAL, CTONG-0802) : a multicentre, open-label, randomised, phase 3 study", Lancet Oncol, 12, pp.735~742 (2011)
- Yang JC, "Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations(LUX-Lung 2) : a phase 2trial", Lancet Oncol, 13, pp.539~548 (2012)
- Sequist LV, "Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors", Sci Transl Med, 3, pp.75~ (2011)
- Suda K, "Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib", J Thorac Oncol, 6, pp.1152~1161 (2011)
- Zhang Z, "Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer", Nat Genet, 44, pp.852~860 (2012)
- Yu HA, "Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFRmutant lung cancers", Clin Cancer Res, 19, pp.2240~2247 (2013)
- Ohashi K, "Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1", Proc Natl Acad Sci U S A, 109, pp.E2127~E2133 (2012)
- Cha MY, "Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models", Int J Cancer, 130, pp.2445~2454 (2012)
- Kim YJ, "Phase I study to evaluate the safety and to assess the food effect of HM781-36B, a novel pan-HER inhibitor continuously given in patients with advanced solid tumors", J Clin Oncol, 31(Suppl) (2013)
- Jackman D, "Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall-cell lung cancer", J Clin Oncol, 28, pp.357~360 (2010)
- Sequist LV, "First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations", J Clin Oncol, 26, pp.2442~2449 (2008)
- Kim ES, "Gefitinib versus docetaxel in previously treated non-smallcell lung cancer(INTEREST) : a randomised phase III trial", Lancet, 372, pp.1809~1818 (2008)
- Gridelli C, "First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer : the TORCH randomized trial", J Clin Oncol, 30, pp.3002~3011 (2012)
- Sequist LV, "Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor : results of a phase II trial in patients with advanced non-small-cell lung cancer", J Clin Oncol, 28, pp.3076~3083 (2010)
- Miller VA, "Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy(LUXLung 1) : a phase 2b", 3 randomised trial, 2012, pp.13, 528~538
- Ellis PM, "Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3trial", Lancet Oncol, 15, pp.1379~1388 (2014)
- Janne PA, "AZD9291 in EGFR inhibitor-resistant nonsmall-cell lung cancer", N Engl J Med, 372, pp.1689~1699 (2015)
- Sequist LV, "Rociletinib in EGFR-mutated non-small-cell lung cancer", N Engl J Med, 372, pp.1700~1709 (2015)
- Tan CS, "Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer", Lung Cancer, 93, pp.59~68 (2016)
- Douillard JY, "First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients : a phase-IV, open-label, singlearm study", Br J Cancer, 110, pp.55~62 (2014)